• Connect Biopharma posted a Q2 net loss of USD 17.3 million, or USD 0.27 per share, widening from USD 12.9 million.
• License and collaboration revenue rose to USD 2.8 million from USD 48,000, driven by a regulatory milestone net of cost sharing.
• R&D expense climbed to USD 16.3 million from USD 8.8 million, reflecting higher rademikibart development spending tied to Seabreeze STAT studies.
• Cash, cash equivalents and short-term investments totaled USD 31.5 million; runway expected to extend at least one year.
• Enrollment completed in Phase 2 Seabreeze STAT asthma and COPD studies; topline data expected in September 2026, with an FDA Phase 3 discussion planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121605PRIMZONEFULLFEED9808787) on August 12, 2026, and is solely responsible for the information contained therein.